Did you know that Cerba Research was present in Australia?
Reach out to our experts and discover how we can help you advance your research
Contact Us
Resource Library
Presence and Capabilities – Running Clinical Trials in Australia Infographic
Resource Library
Resource Library
Fact Sheet – Clinical Trials at Cerba Research
Discover Cerba Research and our clinical trials
Reach out to our experts and discover how we can help advance your research
Contact Us
Resource Library
Fact Sheet – Clinical Trials Autoimmune Diseases at Cerba Research
Did you know that we have extensive experience in researching autoimmune diseases?
Reach out to our experts and discover how we can help advance your research
Contact Us
Resource Library
AACR 2022 poster. Using solid tumor analytical validation of T-regulatory immunohistochemistry multiplex for clinical studies
Our Histoprofile®- T-reg light panel is ready for use in your clinical trials
Accurate characterization of the tumor micro-environment when tissue sample access is limited can be an important challenge in the field of immuno-oncology. The balance and tumor infiltration of T cell subpopulations are of particular interest and its importance has been repeatedly demonstrated in the literature. T cells are important immune effector cells and are therefore preferred targets for immuno-modulation.
Conventional T cells can be broadly classified as helper (Th), cytotoxic (Tcyto), memory or regulatory (Treg) cells. Tcyto cells ensure optimal immune responses against invading microbes and tumor antigens. Under homeostatic conditions, Tregs promote peripheral tolerance. However, within tumors, Tregs can supress Tcyto cell functions. The multiplex protocol, Histoprofile®- T-reg light panel, developed at Cerba Research on the Discovery ULTRA (Ventana) platform is designed to stain specific sub-populations of T cells on a single slide, avoiding the need of serial sections from precious patient’s FFPE samples in clinical trials while still providing an indepth analysis of the tumor microenvironment.
Our in-depth analytical validation ensures the quality of this robust protocol on solid tumor tissues. Evaluate T-cell subpopulations and their spatial distribution in the tumor microenvironment.
Poster – Solid tumor analytical validation of a T-regulatory immunohistochemistry multiplex for clinical studies
Reach out to our experts and discover how we can help advance your clinical trial
Contact Us
Resource Library
Cerba Research’s Multi-Omics Approaches in Hematological Malignancies
Hematological malignancies originate from the uncontrolled growth of hematopoietic and lymphoid tissues. These biologically and clinically heterogeneous disorders account for 6.5% of all cancers worldwide, and for approximately 9.5% of newly diagnosed cancers every year.
Due to the high level of heterogeneity in cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional, and metabolic alterations of hematological diseases, integrated multi-omics analyses are needed to improve clinical outcomes.
At Cerba Research, we aim to bring a multi-modal approach to precision medicine to disease. From discovery to clinical development, we provide world-class teams and capabilities worldwide to help you in your quest for novel treatment against hematological malignancies.
Brochure – Cerba Research's Multi-Omics Approaches in Hematological Malignancies
Reach out to our experts and discover how we can help you advance your research
Contact Us
Resource Library
The Art of Histopathology
Discover the art of histopathology through the eyes of our most skilled scientists.
Immunohistochemistry biomarkers are key players in clinical development success. Tissue biomarkers can aid in the confirmation of diagnosis, patient selection, and/or for mechanistic evaluation.
If you would like to know more about how Cerba Research can help you, our IHC expert scientific team will consult with you on your specific needs. Flexible in our approach and delivery to provide timely and cost effective solutions to meet your clinical and commercial objectives.
Download our digital book to see the art of histopathology for yourself.
Click to download the Art of Histopathology
Reach out to our experts and see how we can help advance your clinical trial
Contact Us
Resource Library
Turning Precision Medicine into Action in Immuno-Oncology
The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.
In this webinar our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.
Speakers
- Jérôme Sallette, PhD, CSO Cerba Research
- Shu Jen Chen, PhD, CSO ACT Genomics
- Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
- George Wei, PhD, Vice President R&D ACT Genomics
- Renaud Burrer, PhD, Head of Histopathology Cerba Research
- Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research
Submit your information below to watch the webinar or to download the slide deck to receive our expert’s insights.
Cerba Research – Webinar – CerbACT turning precision medicine inot action in immuno oncology
Reach out to our experts to see how we can help advance your clinical trial
Contact Us
Resource Library
Advantages and Versatility of Flow Cytometry Considerations for Clinical trial Speciality Lab Outsourcing
It is now clear that the therapeutic future lies in biomarkers through the development of immunotherapies and companion diagnostics. Among the techniques of biomarker analysis, there is Flowcytometry, which allows for precise analysis of liquid samples, but not only.
Validation test development for specific biomarkers is a prerequisite for a successful application in translational research, preclinical and clinical phases. The advantages and disadvantages of this technique, the samples, the conditions of use: Cerba Research will open the doors of its worldwide laboratories for an hour. To answer all your questions about one of the leading techniques of analysis for the development of innovative treatments, our experts will share their knowledge and experience.
Learning Objectives
- What is Flow Cytometry?
- What is the benefit of this technique?
- How is it implemented in clinical trials?
- Assays management details
Speakers
Nithianandan Selliah, Ph.D., Global Head of Flow Cytometry at Cerba Research
Nithianandan obtained his PhD in Immunology and started to work on HIV research. After more than 10 years of HIV research, he joined a biotech company to work on biomarker discovery for autoimmune diseases. His interest in Flow cytometry at the biotech company lead him to join global CRO to work on assay development and validation in Flow cytometry for global clinical trials. He joined Cerba Research to continue to work on his passion of Flow cytometry in clinical trial and takes on new challenges to build the best Flow cytometry service to the clients.
He is working with exceptional scientific teams in US and Belgium to bring on new assays for various therapeutic indications, including Immuno-oncology and autoimmune diseases.
Ishita Modi, Director, Scientific Customer Solutions at Cerba Research
A microbiologist by education, Ishita finished her studies from Gujarat University in India, and moved on to starting her career in United States. She has more than 15 years of experience in clinical and diagnostic research industry. Her expertise is in building a strong foundation of clinical operations and clinical research with commitment to meeting client’s scientific needs to help advance medicine. Ishita has worked at CRO/Central Lab as well as at some of the leading clinical diagnostic labs in the region. Her scientific expertise includes infectious diseases and genetics, and gained extensive experience in microbiology, virology and molecular biology. Ishita is a New York State certified Medical Technologist and also certified IRB (Institutional Review Board) professional. Her experience over the years has made her very strong in all aspects of clinical research and regulatory requirements. She has a passion for advancing science and making a difference in the future of healthcare.
Webinar – Advantages and Versatility of Flow Cytometry Considerations for Clinical trial Speciality Lab Outsourcing
Reach out to our experts to see how we can help advance your clinical trial
Contact Us
Resource Library
Precision medicine for non-small cell lung cancer (NSCLC) – Emerging trends in molecular analysis
Of all types of cancer, lung cancer caused more deaths worldwide than any other type of cancer. It also causes more deaths than breast and colorectal cancers combined. Patients with the most common lung cancer, non-small cell lung cancer (NSCLC), have higher survival rates than patients with small-cell lung cancer (SCLC), but the outcomes for both remain bleak. According to the National Cancer Institute, the five-year survival rate for NSCLC between 2004 and 2010 was 20.7% compared to only 6.3% for SCLC.2
NSCLC patients also have more promising and more precise, treatment options today compared to even 10 years ago. Advances in biomarker and precision medicine have led to the development of immunotherapies and targeted novel treatments that have the potential to improve patient outcomes. In the United States, the FDA has approved dozens of biomarker-driven therapies for NSCLC, including ALK, EGFR, and ROS1 inhibitors. Meanwhile, more than 1,200 treatments are in development.
Discover the latest trends in precision medicine for NSCLC in this white paper
White Paper – Precision Medicine for non small cell lung cancer – NSCLC
Reach out to our experts to see how we can help advance your clinical trial
Contact Us
Resource Library
Flow Cytometry At Cerba Research – From Client Conversations To Central Review
Discover in a nutshell how we at Cerba Research perform flow cytometry, from a to z, from client to central review.
Reach out to our experts to discover how we can help you further in the field of flow cytometry
Contact Us